Valuation: Incyte Corporation

Market Cap 22.65B 19.82B 18.3B 17.07B 32.16B 2,141B 32.74B 219B 85.22B 1,057B 85.09B 83.19B 3,681B P/E 2026 *
16.5x
P/E 2027 * 14.3x
Enterprise Value 17.63B 15.43B 14.24B 13.29B 25.03B 1,667B 25.48B 171B 66.33B 823B 66.23B 64.75B 2,865B EV / Sales 2026 *
3.12x
EV / Sales 2027 * 2.54x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day-1.13%
1 week+8.58%
1 month+17.18%
3 months+20.44%
6 months+14.77%
Current year+14.77%
1 week 106.48
Extreme 106.48
115.56
1 month 92.18
Extreme 92.18
115.56
Current year 89.25
Extreme 89.25
115.56
1 year 66.85
Extreme 66.85
115.56
3 years 50.27
Extreme 50.27
115.56
5 years 50.27
Extreme 50.27
115.56
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

7,753 0.0039%
06-07
FBS Associates LLC
OtherCompany 0 0%
06-07
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%+8.58%+66.46%+82.10% 22.91B
-1.31%+0.89%+18.77%-13.22% 64.28B
-0.57%+4.09%+56.93%+222.66% 57.29B
-3.94%+39.10%+39.10%+39.10% 43.45B
+1.60%+1.18%-51.16%-57.88% 38.02B
-0.26%+9.57%+72.04%-24.15% 31.98B
+0.47%+14.80%+153.82%-42.36% 27.66B
-0.56%+4.05%+1.53%+168.92% 17.74B
-0.13%-0.94%+60.31%+119.58% 16.45B
+3.43%+8.52%+72.49%+333.02% 14.1B
Average -0.26%+5.62%+49.03%+82.78% 33.39B
Weighted average by Cap. -0.66%+4.66%+42.96%+62.90%

Financials

2026 *2027 *
Net sales 5.65B 4.94B 4.56B 4.26B 8.02B 534B 8.16B 54.72B 21.24B 263B 21.21B 20.74B 918B 6.22B 5.44B 5.02B 4.69B 8.83B 588B 8.99B 60.26B 23.39B 290B 23.36B 22.84B 1,011B
Net income 1.44B 1.26B 1.16B 1.08B 2.04B 136B 2.08B 13.93B 5.41B 67.05B 5.4B 5.28B 234B 1.67B 1.47B 1.35B 1.26B 2.38B 158B 2.42B 16.22B 6.3B 78.1B 6.29B 6.15B 272B
Net Debt -5.02B -4.39B -4.06B -3.78B -7.13B -475B -7.25B -48.64B -18.88B -234B -18.86B -18.43B -816B -6.87B -6.02B -5.55B -5.18B -9.76B -650B -9.94B -66.62B -25.86B -321B -25.83B -25.25B -1,117B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
30/06/26 US$113.36 -1.13% 1,829,336
29/06/26 US$114.66 +0.80% 1,532,380
26/06/26 US$113.75 +5.78% 3,795,266
25/06/26 US$107.53 -0.86% 1,832,481
24/06/26 US$108.46 +3.89% 1,963,908
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
113.36USD
Average target price
111.27USD
Spread / Average Target
-1.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock